U.S. regulators on Friday approved AbbVie Inc.’s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.

The U.S. Food and Drug Administration approved AbbVie’s Viekira Pak, a cocktail of several drugs that cured more than 90% of people with the most common subtype of hepatitis C in the U.S., genotype 1, in clinical trials. The regimen consists of several pills taken daily for about 12 weeks, eliminating the need for an older injected drug, interferon, which many patients find difficult to tolerate.